Dyslipidemias: Clinical Trials

357 trials for Dyslipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

242 completed, 57 unknown, 19 terminated, 12 recruiting. 357 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4357Completed 242, Unknown 57, Terminated 19, Recruiting 12, Withdrawn 12, Not yet recruiting 7, Active not recruiting 5, Enrolling by invitation 2, Suspended 1

Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias

Trials (filtered) newest first · largest first

All 357 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia
Phase 4Not yet recruitingAmgen3082027-01-312026-09-21
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease
Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA
Phase 4Not yet recruitingRehman Medical Institute - RMI1782026-11-012026-11-05
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
inclisiran, SOC - Acute Coronary Syndrome
Phase 4Not yet recruitingNovartis Pharmaceuticals3002026-10-312026-10-30
GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
Semaglutide, Placebo (Normal Saline) - Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis
Phase 4Not yet recruitingPeking Union Medical College Hospital3962026-09-012026-06-01
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
bempedoic acid, Ezetimibe, High-Intensity Statin Therapy - Acute Coronary Syndromes, Dyslipidemia
Phase 4RecruitingTaipei Medical University Hospital4002026-08-262026-09-17
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT
icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy - Coronary Artery Disease, Hyperlipidaemia
Phase 4Not yet recruitingChina National Center for Cardiovascular Diseases1002026-08-012026-08-13
A Post-Marketing Clinical Trial of Pemafibrate in Patients ο½—ith Hypercholesterolemia and Inadequate Response to Statins
Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day, Placebo - Hypercholesterolemia
Phase 4RecruitingKowa Company, Ltd.1202026-07-012026-07-13
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
Tirzepatide - Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease
Phase 4Enrolling by invitationNational Taiwan University Clinical Trial Center602026-06-252026-07-20
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Phase 4RecruitingUniversity Medical Centre Ljubljana602026-05-182026-06-02
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Atorvastatin 40 Mg Oral Tablet, Ezetimibe 10 mg, Bempedoic Acid 180 MG Oral Tablet - Acute Coronary Syndromes (ACS), Hypercholesterolemia
Phase 4Not yet recruitingPunjab Institute of Cardology1202026-05-012026-04-09
Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE), Standard Care (in control arm) - Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced
Phase 4RecruitingJianyin Zhou1802026-01-182026-07-22
Yangxin Dawayimixike Honey Paste for Carotid Atherosclerotic Plaque With Dyslipidemia: A Randomized Controlled Clinical Study
Yangxin Dawayimixike Honey Paste, Yangxin Dawayimixike Honey Paste placebo - Dyslipidemia, Carotid Atherosclerotic Plaques
Phase 4Not yet recruitingXinjiang Uygur Pharmaceutical Co., Ltd.4222026-01-012026-01-02
Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
Rosuvastatin + Ezetimibe, Bempedoic Acid + Ezetimibe, Rosuvastatin + Ezetimibe + Bempedoic Acid - Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol
Phase 4CompletedBahria University1262026-01-012026-10-20
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Educational Material, Standard of care - Atherosclerotic Cardiovascular Disease
Phase 4RecruitingNovartis Pharmaceuticals3262025-11-262026-05-04
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo) - Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4RecruitingDuke University60002025-07-232026-10-29
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
early time restricted Mediterranean diet, Mysimba - Diabetes Mellitus, Type 2, Liver Fibrosis
Phase 4Enrolling by invitationCarmen Dietvorst702025-04-142026-04-21
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
Bempedoic acid 180 mg tablet - Primary Hypercholesterolemia or Mixed Hyperlipidemia
Phase 4CompletedDaiichi Sankyo1802025-04-012025-12-08
LATAM LOWERS LDL-C
Usual care, KJX839 - Hypercholesterolaemia
Phase 4RecruitingNovartis Pharmaceuticals5202025-02-112025-12-30
Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population
Atorvastatin 10 mg and ezetimibe 10 mg, Atorvastatin 20 mg - Hyperlipidemia (E.G., Hypercholesterolemia)
Phase 4WithdrawnDr. Md. Alimur Reza2025-02-012026-10-07
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Inclisiran - Atherosclerotic Cardiovascular Disease
Phase 4Active not recruitingDuke University1302024-12-162026-07-29

Showing 20 of 357. Sign in to see all of them.

Narrower conditions

Hypercholesterolemia (148)  ·  Hyperlipidemias (71)  ·  Diabetes Mellitus, Type 2 (41)  ·  Hypertension (38)  ·  Hypertriglyceridemia (35)  ·  Diabetes Mellitus (32)  ·  Atherosclerosis (31)  ·  Cardiovascular Diseases (30)  ·  Coronary Artery Disease (26)  ·  Coronary Disease (16)  ·  Insulin Resistance (15)  ·  HIV Infections (13)  ·  Hyperlipoproteinemia Type II (12)  ·  Metabolic Syndrome (11)

Broader conditions

Nutritional and Metabolic Diseases (356)  ·  Metabolic Diseases (355)  ·  Lipid Metabolism Disorders (349)  ·  Hyperlipidemias (173)  ·  Vascular Diseases (117)  ·  Cardiovascular Diseases (104)  ·  Glucose Metabolism Disorders (80)  ·  Endocrine System Diseases (68)  ·  Arterial Occlusive Diseases (57)  ·  Arteriosclerosis (57)  ·  Myocardial Ischemia (51)  ·  Heart Diseases (50)  ·  Pathological Conditions, Signs and Symptoms (43)  ·  Diabetes Mellitus (34)

Interventions

Atorvastatin (70)  ·  Ezetimibe (50)  ·  Rosuvastatin Calcium (46)  ·  Simvastatin (34)  ·  Fenofibrate (20)  ·  Omacor (14)  ·  evolocumab (14)  ·  pitavastatin (14)  ·  Niacin (13)  ·  Pravastatin (13)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (12)  ·  Amlodipine (11)  ·  Ezetimibe, Simvastatin Drug Combination (11)  ·  alirocumab (9)  ·  Colesevelam Hydrochloride (8)

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (23)  ·  Organon and Co (19)  ·  Yonsei University (10)  ·  Gachon University Gil Medical Center (9)  ·  Takeda (8)  ·  AstraZeneca (7)  ·  Daiichi Sankyo (7)  ·  Novartis Pharmaceuticals (7)  ·  Novartis (5)  ·  Seoul National University Hospital (5)  ·  JW Pharmaceutical (4)  ·  Seoul National University Bundang Hospital (4)  ·  University of Ioannina (4)  ·  Yuhan Corporation (4)  ·  Duke University (3)

Countries

United States (73)  ·  South Korea (51)  ·  China (22)  ·  Japan (19)  ·  Italy (15)  ·  Spain (14)  ·  Germany (13)  ·  Canada (10)  ·  Taiwan (9)  ·  France (8)  ·  United Kingdom (8)  ·  Greece (7)  ·  Belgium (6)  ·  Brazil (6)  ·  Israel (6)

Top investigators

Andrew D Carr, MD (2)  ·  Ann-Brit E Hansen, M.D. (2)  ·  Court Pedersen, Professor (2)  ·  David A Cooper, MD (2)  ·  Jan Gerstoft, M.D., DMSc (2)  ·  Jifei Tang, MD (2)  ·  Kevin C. Maki, PhD (2)  ·  Lawrence Baruch, MD (2)

Results publications

PMID 38018702, PMID 21297494, PMID 10069782, PMID 10323786, PMID 10367822, PMID 10529901, PMID 10593347, PMID 10946791, PMID 11009277, PMID 11339434, PMID 11558482, PMID 11781675, PMID 11849859, PMID 12379573, PMID 12652104, PMID 15249516, PMID 15329324, PMID 15364185, PMID 15505289, PMID 15611492, PMID 16310551, PMID 16404415, PMID 16749654, PMID 16893434, PMID 16923260, PMID 17011942, PMID 17190864, PMID 17407633, PMID 17578790, PMID 17626713, PMID 17635891, PMID 17668878, PMID 17711927, PMID 17804683, PMID 17827859, PMID 17898099, PMID 18070815, PMID 18172039, PMID 18312764, PMID 18332269, PMID 18398080, PMID 18404599, PMID 18413554, PMID 18519429, PMID 18545068, PMID 18559695, PMID 18653575, PMID 18762410, PMID 18955731, PMID 19060422

NIH funding

2015 (2), 2018 (2), 2004 (1), 2005 (1), 2016 (1), 2023 (1), K23AT002862 (1), K23HL169929 (1), R01AR071263 (1), R01DK061486 (1), R01HL063055 (1), R01HL075824 (1), R01HL096585 (1), R01MH071536 (1), R21AT003083 (1)